Updated Jan 22, 2021 | 12:00 IST
Shares of Biocon saw a steep fall after the drugmaker s results missed analyst estimates in the quarter ended December. Net profit declined 19% year-on-year as expenses rose significantly. Biocon earnings | Photo Credit: BCCL
Key Highlights
Biocon says it continues to face headwinds across operational, regulatory and commercial function Dr. Christiane Hamacher steps down as the Managing Director of Biocon Biologics Limited due to professional differences with the Chairperson on strategic priorities and vision for the company
Mumbai: Biocon was one of the top laggards on Dalal Street today as the company declared it’s earnings, however, the earnings were a miss compared to the consensus street estimates that were pencilled in. Below are the key highlights of the earnings report by Biocon.
Infected? Still Take The Vaccine, Says Bharat Biotech Chairman
India is well prepared for distribution and Indian immunisation system is very robust, says Krishna Ella
PTI 23 December 2020 outlookindia.com 2020-12-23T19:29:56+05:30
Also read
People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech Chairman & MD Krishna Ella said on Wednesday.
He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post-vaccination era organised by industry body CII.
For the people who are infected, should they take a vaccine, the answer is yes , because they may not have a good T cells response. Ella said.
People who are infected should also take vaccine: Bharat Biotech Chairman Krishna Ella
Krishna Ella was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post vaccination era organised by industry body CII. PTI December 23, 2020 / 08:29 PM IST
People who are infected should also take a vaccine, and India is well prepared regarding the logistics for the vaccine distribution, Bharat Biotech Chairman & MD Krishna Ella said on Wednesday.
He was speaking in a virtual session on Sero surveillance significance in immunogenicity and safety in pre and post vaccination era organised by industry body CII.
Kiran Mazumdar-Shaw, Chairperson, In 1978, when I founded Biocon, I was India’s first qualified woman brew-master, yet no one was willing to offer me a job. Being a young woman, I had to be assertive to prove my worth at every point. I had no financial backing or business experience, and no banks were willing to give me loans without a collateral or my father’s guarantee, which I did not want. I was, as a 25-year-old, trying to pioneer a new sector, biotechnology, which no banker was familiar with. I was considered a huge investment risk. I was often advised to take on board my father as a business partner to facilitate the process. However, even though raising debt was extremely difficult, my perseverance brought me an angel investor who gave me the required funds to scale up my business against an equity stake in the company. Fortunately, today the startup ecosystem is well supported by venture capital firms.